How Much Did Neuroplast Raise?
Funding & Key Investors

Neuroplast, a Dutch stem cell technology firm, has secured $11.5M in total capital, with its most recent funding round bringing in $11.5M through a major strategic investment. This significant backing underscores the company's progress in developing autologous cell products for neurological disorders.

What is Neuroplast?

Neuroplast
Business ServicesResearch & Development

Neuroplast is a Dutch company specializing in stem cell technology, founded in August 2014 by physician Johannes de Munter and neurologist Erik Wolters. The company focuses on fast-track development programs utilizing autologous cell products to treat inflammation-driven neurological disorders. Neuroplast aims to provide new therapeutic perspectives for individuals suffering from these conditions. The company is strategically located at the Brightlands Chemelot Campus in The Netherlands, a hub for innovation in materials and life sciences.

How much funding has Neuroplast raised?

Neuroplast has raised a total of $11.5M across 1 funding round:

2021

Series B

$11.5M

Series B (2021): $11.5M with participation from Liof and Brightlands Venture Partners

Key Investors in Neuroplast

Liof

LIOF is the regional development agency for Limburg, dedicated to supporting innovative entrepreneurs through advice, networking, and financing. Their services are aimed at startups, scale-ups, and SMEs looking to innovate, invest, or internationalize, with a focus on creating a smarter, more sustainable, and healthier Limburg.

Brightlands Venture Partners

Brightlands Venture Partners (BVP) invests in innovative companies that address global challenges in health, agrifood, and renewable chemistry. They focus on partnering with outlier founders who possess deep domain expertise and the ambition to build scalable businesses.

What's next for Neuroplast?

With the recent major strategic investment, Neuroplast is poised to accelerate its development programs for novel stem cell therapies targeting neurological conditions. The substantial capital infusion, part of its overall $11.5M in financing, will likely support further clinical trials, research initiatives, and the scaling of its proprietary autologous cell product platform. This strategic backing from key investors signals strong confidence in Neuroplast's potential to address unmet needs in the treatment of inflammation-driven neurological disorders.

See full Neuroplast company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Business Services industry

Business ServicesResearch & DevelopmentConsumer ServicesRepair Services
Business ServicesHuman Resources Management Systems (HRMS)Accounting for Legal Practices
Advertising NetworksBusiness Services
Business ServicesResearch & DevelopmentChemicals & Related ProductsManufacturing

Frequently Asked Questions Regarding Neuroplast Financial Insights

What are the most recent funding rounds that Neuroplast has completed, and what were the funding rounds?
Neuroplast has recently completed 1 funding rounds: Series B on Nov 17, 2021.
What is the total amount of funding Neuroplast has raised to date?
Neuroplast has raised a total of $11.5M in funding to date.
How many funding rounds has Neuroplast completed?
Neuroplast has completed 1 funding rounds.
How much funding did Neuroplast raise in its most recent funding round?
Neuroplast raised $11.5M in its most recent funding round.
Who are the lead investors in Neuroplast's latest funding round?
The lead investor in Neuroplast's latest funding round was Liof. To access investor data and explore similar companies, sign up for ZoomInfo.
Which was the largest funding round in Neuroplast's history?
The largest funding round in Neuroplast's history was $11.5M.
See more information about Neuroplast